Islam Gamaleddin
Overview
Explore the profile of Islam Gamaleddin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
383
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Al-Harbi F, Gamaleddin I, Alsubaie E, Al-Surimi K
Oman Med J
. 2020 Apr;
35(2):e110.
PMID: 32257419
Objectives: Anabolic-androgenic steroids (AAS) have been used internationally for enhancing physical appearance and performance despite their significant side effects. We sought to identify the prevalence of AAS use and its...
2.
Alharbi F, Gamaleddin I, Alharbi S, Almodayfer O, Allohidan F, Alghobain M, et al.
Saudi Pharm J
. 2019 Feb;
27(2):254-263.
PMID: 30766438
Recreational use of anabolic-androgenic steroids (AAS) is a growing worldwide public health concern. However, studies assessing the level of awareness and knowledge of its effects on health are fairly limited,...
3.
Trigo J, Lagzdins D, Rehm J, Selby P, Gamaleddin I, Fischer B, et al.
Drug Alcohol Depend
. 2016 Mar;
161:298-306.
PMID: 26925704
Background: There is currently no pharmacological treatment approved for cannabis dependence. In this proof of concept study, we assessed the feasibility/effects of fixed and self-titrated dosages of Sativex (1:1, Δ(9)-tetrahydrocannabinol...
4.
Forget B, Guranda M, Gamaleddin I, Goldberg S, Le Foll B
Psychopharmacology (Berl)
. 2016 Feb;
233(10):1823-8.
PMID: 26864774
Rationale: The endocannabinoid system is composed of endocannabinoids (such as anandamide), their target receptors (CB1 and CB2 receptors, CB1Rs and CB2Rs), the enzymes that degrade them (fatty-acid-amide-hydrolase (FAAH) for anandamide),...
5.
Di Ciano P, Guranda M, Lagzdins D, Tyndale R, Gamaleddin I, Selby P, et al.
Neuropsychopharmacology
. 2015 Oct;
41(6):1513-20.
PMID: 26442600
Varenicline, a nicotinic partial agonist, is the most effective treatment for tobacco use disorder. However, its mechanism of action is still unclear and may involve stimulating dopaminergic transmission. Here we...
6.
Samokhvalov A, Gamaleddin I, Sproule B, Rehm J
BMJ Case Rep
. 2013 Aug;
2013.
PMID: 23925680
Naltrexone is a first-line treatment for alcohol use disorders in North America and Europe. It was prescribed to a 63-year-old patient in order to help control amounts of alcohol consumed...
7.
Gamaleddin I, Guranda M, Scherma M, Fratta W, Makriyannis A, Vadivel S, et al.
J Psychopharmacol
. 2013 Feb;
27(6):564-71.
PMID: 23427192
Multiple studies suggest a pivotal role of the endocannabinoid system in the regulation of the reinforcing effects of various substances of abuse. Different approaches have been used to modulate endocannabinoid...
8.
Yan Y, Pushparaj A, Gamaleddin I, Steiner R, Picciotto M, Roder J, et al.
Behav Brain Res
. 2012 Feb;
230(1):34-9.
PMID: 22326373
The ability to examine genetically engineered mice in a chronic intravenous (IV) nicotine self-administration paradigm will be a powerful tool for investigating the contribution of specific genes to nicotine reinforcement...
9.
Gamaleddin I, Zvonok A, Makriyannis A, Goldberg S, Le Foll B
PLoS One
. 2012 Feb;
7(1):e29900.
PMID: 22291896
Over the last decade there have been significant advances in the discovery and understanding of the cannabinoid system along with the development of pharmacologic tools that modulate its function. Characterization...
10.
Yan Y, Pushparaj A, Le Strat Y, Gamaleddin I, Barnes C, Justinova Z, et al.
Neuropsychopharmacology
. 2011 Oct;
37(3):685-96.
PMID: 22030716
Since cloning of the dopamine receptor D4 (DRD4), its role in the brain has remained unclear. It has been reported that polymorphism of the DRD4 gene in humans is associated...